A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer
Current Oncology · 25.12.2024 · 32 (1) · 6
DOI: 10.3390/curroncol32010006 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Current Oncology, online erschienen am 25.12.2024. Verfasst von Danilo Giffoni de Mello Morais Mata und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Verspeeten Family Cancer Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada. Hauptthemen laut MEDLINE: Cyclophosphamide, Breast Neoplasms, Docetaxel, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Anthracycline–taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC).
Methods
Through a retrospective study of stage I-III HER2-negative BC, using administrative databases, we analyzed a total of 10,634 women treated with adjuvant chemotherapy in Ontario, Canada, between 2009 and 2017. We compared TC versus standardized anthracycline–taxane chemotherapies (ACT and FEC-D). We investigated the overall survival (OS), and explored the incidence of CHF, emergency department (ED) visits and febrile neutropenia.
Results
With a median follow-up of 5.5 years, the 5-year analysis showed an increased OS in patients treated with TC, versus those treated with ACT, HR 0.77 (0.63–0.95, p = 0.015). Among ER+ BC, there was an increased OS in patients treated with ACT and FEC-D, versus those treated with TC, HR 0.70 (0.52–0.95, p = 0.021) and HR 0.71 (0.56–0.91, p = 0.007), respectively. There were no substantial differences in CHF, between TC and anthracycline-based treatments. Patients treated with TC and FEC-D had more ED visits, compared to those treated with ACT.
Conclusion
Our study shows that anthracycline–taxane regimens were the most commonly prescribed adjuvant chemotherapy options in HER2-negative BC. Women who received ACT had the lowest OS, likely due to their unfavorable pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Verspeeten Family Cancer Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada.
- Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada.
- ICES Western, London, ON N6A 5W9, Canada.
- Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
- Department of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada.
- Cancer Program, ICES, Toronto, ON M4N 3M5, Canada.
ORCID-Profile: Danilo Giffoni de Mello Morais Mata, Maureen Trudeau
Zitieren
APA
Giffoni de Mello Morais Mata, D., Pezo, R. C., Chan, K. K. W., Menjak, I., Eisen, A., & Trudeau, M. (2024). A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer. Current Oncology, 32(1), 6. https://doi.org/10.3390/curroncol32010006
Vancouver
Giffoni de Mello Morais Mata D, Pezo RC, Chan KKW, Menjak I, Eisen A, Trudeau M. A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer. Current Oncology. 2024;32(1):6. doi:10.3390/curroncol32010006
BibTeX
@article{GiffonideMelloMoraisMata2024,
author = {Giffoni de Mello Morais Mata, Danilo and Pezo, Rossanna C and Chan, Kelvin K W and Menjak, Ines and Eisen, Andrea and Trudeau, Maureen},
title = {A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer},
journal = {Current Oncology},
year = {2024},
volume = {32},
number = {1},
pages = {6},
doi = {10.3390/curroncol32010006}
}
EUVIMED